Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: The role of informal caregiving and household factors

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue SUPPL. 2, 2007, Pages

  Knowlton, Amy R ^a   Arnsten, Julia H ^b   Gourevitch, Marc N ^c   Eldred, Lois ^d   Wilkinson, James D ^e   Rose, Carol Dawson ^f   Buchanan, Amy ^a   Purcell, David W ^g  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adherence; Highly active antiretroviral therapy effectiveness; HIV AIDS; Home and community care; Illicit injection drug users; Social support structures

Indexed keywords

ADULT; ARTICLE; DRUG USE; EMOTIONALITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOCIAL ENVIRONMENT; SOCIAL ISOLATION; SOCIAL SUPPORT; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SOCIAL SUPPORT; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; TREATMENT REFUSAL; UNITED STATES; VIRAL LOAD;

EID: 37349096983     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815767f8     Document Type: Article

References (64)

1. Simoni JM, Pearson CR, Pantalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23-S35.
2. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol. 2005;161:999-1012.
3. Di Matteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207-218.
4. Persson L, Ostergren PO, Hanson BS, et al. Social network, social support, and the rate of decline of CD4 lymphocytes in asymptomatic HIV-positive homosexual men. Scand J Public Health. 2002;30:184-190.
5. Leserman J, Petitto JM, Gu H, et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002;32:1059-1073.
6. Burgoyne RW. Exploring direction of causation between social support and clinical outcome for HIV-positive adults in the context of highly active antiretroviral therapy. AIDS Care. 2005;17:111-124.
7. Van Servellen G, Lombardi E. Supportive relationships and medication adherence in HIV-infected, low-income Latinos. West J Nurs Res. 2005;27:1023-1039.
8. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537-544.
9. Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16:625-633.
10. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599-1605.
11. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS. 2003;17:645-656.
12. Remien RH, Hirky AE, Johnson MO, et al. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7:61-72.
13. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr. 2004;35:46-51.
14. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
15. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
16. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
17. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573-580.
18. Palepu A, Horton NJ, Tibbetts N, et al. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99:361-368.
19. Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39:1190-1198.
20. Purkayastha T, Wasi F, Shuter J. Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinic. AIDS Patient Care STDS. 2005;19:785-793.
21. Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med. 2003;10:1-14.
22. Chesney MA. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17:169-177.
23. Rabkin JG, Johnson J, Lin SH, et al. Psychopathology in male and female HIV-positive and negative injecting drug users: longitudinal course over 3 years. AIDS. 1997;11:507-515.
24. Knowlton AR, Arnsten JH, Gourevitch MN, et al. Individual, interpersonal, and structural correlates of effective highly active antiretroviral therapy use among urban active injection drug users. J Acquir Immune Defic Syndr. 2006;41:486-492.
25. Pearlin LI, Mullan JT, Aneshensel CS, et al. The structure and functions of AIDS caregiving relationships. Psychiatr Rehabil J. 1994;17:51-67.
26. Arno P, Levine C, Memmott M. The economic value of informal caregiving. Health Aff. 1998;18:182-188.
27. Young J, De Geest S, Spirig R, et al. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. BMJ. 2004;328:15-20.
28. Wardlaw LA. Sustaining informal caregivers for persons with AIDS. Fam Soc. 1994;75:373-384.
29. Wight RG, LeBlanc AJ, Aneshensel CS. Support service use by persons with AIDS and their caregivers. AIDS Care. 1995;7:509-520.
30. Samet JH, Freedberg KA, Stein MD, et al. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med. 1998;158:734-740.
31. Knowlton A. Informal HIV caregiving in a vulnerable population: toward a network resource framework. Soc Sci Med. 2003;56:1307-1320.
32. Johnston D, Stall R, Smith K. Reliance by gay men and intravenous drug users on friends and family for AIDS-related care. AIDS Care. 1995;7:307-319.
33. Knowlton A, Hua W, Latkin C. Social support among HIV positive injection drug users: implications to integrated intervention for HIV positives. AIDS Behav. 2004;8:357-363.
34. Knowlton A, Hua W, Latkin C. Social support networks and medical service use among HIV-positive injection drug users: implications for intervention. AIDS Care. 2005;17:479-492.
35. Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS. 2005;19:326-334.
36. Godin G, Cote J, Naccache H, et al. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care. 2005;17:493-504.
37. Pratt RJ, Robinson N, Loveday HP, et al. Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice. HIV Clin Trials. 2001;2:146-159.
38. Lloyd JJ, Ricketts EP, Strathdee SA, et al. Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse. 2005;31:555-570.
39. Schroeder JR, Latkin CA, Hoover DR, et al. Social factors related to antiretroviral therapy use in injection drug users. AIDS Behav. 2001;5:363-369.
40. Siegel K, Schrimshaw EW, Raveis VH. Accounts for non-adherence to antiretroviral combination therapies among older HIV-infected adults. Psychol Health Med. 2000;5:29-42.
41. Golin C, Isasi F, Bontempi JB, et al. Secret pills: HIV-positive patients' experiences taking antiretroviral therapy in North Carolina. AIDS Educ Prev. 2002;14:318-329.
42. Folkman S, Chesney MA, Christopher-Richards A. Stress and coping in caregiving partners of men with AIDS. Psychiatr Clin North Am. 1994;17:35-53.
43. Parsons JT, Van Ora J, Missildine W, et al. Positive and negative consequences of HIV disclosure among seropositive injection drug users. AIDS Educ Prev. 2004;16:459-475.
44. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47-58.
45. Bakken S, Holzemer WL, Brown MA, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS. 2000;14:189-197.
46. Demmer C. Relationship with health care provider and adherence to HIV medications. Psychol Rep. 2003;93:494-496.
47. Schneider J, Kaplan SH, Greenfield S, et al. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004;19:1096-1103.
48. Goldstein RB, Rotherman-Borus MJ, Johnson MO, et al. Insurance coverage, usual source of care, and receipt of clinically indicated care for comorbid conditions among adults living with human immunodeficiency virus. Med Care. 2005;43:401-410.
49. Clarke S, Delamere S, McCullough L, et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med. 2003;4:33-37.
50. Purcell DW, Metsch LR, Latka M, et al. Interventions for seropositive injectors - research and evaluation: an integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. J Acquir Immune Defic Syndr. 2004;37(Suppl):S110-S118.
51. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. MMWR Morb Mort Wkly Rep. 2002;51:40.
52. Derogatis LR, Spencer PM. The Brief Symptom Inventory (BSI): Administration, Scoring, and Procedural Manual - 1. Baltimore, MD: John Wiley; 1982.
53. Mizuno Y, Purcell DW, Dawson-Rose C, et al. Correlates of depressive symptoms among HIV-positive injection drug users: the role of social support. AIDS Care. 2003;15:689-698.
54. Ewart CK. Social action theory for a public health psychology. Am Psychol. 1991;46:931-946.
55. Pescosolido B, Levy J. The role of social networks in health, illness, disease and healing: the accepting present, the forgotten past and the dangerous potential for a complacent future. In: Levy J, Pescosolido B, eds. Social Networks and Health. Amsterdam, The Netherlands: JAI; 2002:3-25.
56. Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care STDS. 2004;18:385-393.
57. Thoits PA. Stress, coping, and social support processes: where are we? What next? J Health Soc Behav. 1995;Spec No:53-79.
58. Knowlton AR, Latkin CA. Network financial support and conflict as predictors of depressive symptoms among a disadvantaged population. J Community Psychol. 2007;35:13-28.
59. Knowlton AR, Curry A, Wissow L, et al. Depression and social context: characteristics of primary supporters as correlates of depression among HIV positive drug users. J Commun Psychol. (in press).
60. Clark RE. Family costs associated with severe mental illness and substance use. Hosp Community Psychiatry. 1994;45:808-813.
61. Wight RG. Precursive depression among HIV infected AIDS caregivers over time. Soc Sci Med. 2000;51:759-770.
62. Joseph EB, Bhatti RS. Psychosocial problems and coping patterns of HIV seropositive wives of men with HIV/AIDS. Soc Work Health Care. 2004;39:29-47.
63. Pearlin LI, Aneshensel CS, LeBlanc AJ. The forms and mechanisms of stress proliferation: the case of AIDS caregivers. J Health Soc Behav. 1997;38:223-236.
64. LeBlanc AJ, London AS, Aneshensel CS. The physical costs of AIDS caregiving. Soc Sci Med. 1997;45:915-923.